Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Haemonetics reported revenue of $321.39 million for the quarter ended June 2025, reflecting a year-over-year decline of 4.4% [1] - The earnings per share (EPS) for the same period was $1.10, compared to $1.02 a year ago, indicating an increase [1] - The reported revenue exceeded the Zacks Consensus Estimate of $303.28 million by 5.97%, while the EPS surpassed the consensus estimate of $1.01 by 8.91% [1] Revenue Breakdown - Plasma segment net revenues were $129.9 million, exceeding the average estimate of $113.65 million by three analysts, but showing a year-over-year decline of 4.4% [4] - Hospital segment net revenues reached $139.66 million, slightly below the average estimate of $144.4 million, with a year-over-year increase of 4.2% [4] - Blood Center segment net revenues were $51.84 million, surpassing the average estimate of $46.38 million, but reflecting a significant year-over-year decline of 21.8% [4] Stock Performance - Haemonetics shares have returned -2.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]